Law360, New York (October 01, 2009) -- A judge has ruled that a Roche Palo Alto LLC patent used for the formulation of its anti-viral drug Valcyte is valid but that Ranbaxy Laboratories Ltd.’s generic version of the drug does not infringe it.
In a detailed 92-page order Judge Freda Wolfson of the U.S. District Court for the District of New Jersey said that Ranbaxy had failed to prove that the patent in...
